Switch to:

GuruFocus Financial Strength Rank measures how strong a company’s financial situation is. It is based on these factors

1. The debt burden that the company has as measured by its Interest coverage (current year).
2. Debt to revenue ratio. The lower, the better
3. Altman Z-score.

A company ranks high with financial strength is likely to withstand any business slowdowns and recessions.

Financial Strength : 3/10

vs
industry
vs
history
Cash to Debt No Debt
SSRX's Cash to Debt is ranked lower than
127% of the 841 Companies
in the Global Biotechnology industry.

( Industry Median: 60.34 vs. SSRX: No Debt )
Ranked among companies with meaningful Cash to Debt only.
SSRX' s 10-Year Cash to Debt Range
Min: 0.2  Med: 10000.00 Max: No Debt
Current: No Debt
Equity to Asset 0.90
SSRX's Equity to Asset is ranked lower than
179% of the 594 Companies
in the Global Biotechnology industry.

( Industry Median: 0.69 vs. SSRX: 0.90 )
Ranked among companies with meaningful Equity to Asset only.
SSRX' s 10-Year Equity to Asset Range
Min: 0.16  Med: 0.90 Max: 0.97
Current: 0.9
0.16
0.97
Interest Coverage No Debt
SSRX's Interest Coverage is ranked lower than
284% of the 375 Companies
in the Global Biotechnology industry.

( Industry Median: 10000.00 vs. SSRX: No Debt )
Ranked among companies with meaningful Interest Coverage only.
SSRX' s 10-Year Interest Coverage Range
Min: 1  Med: 10000.00 Max: 1000
Current: No Debt
1
1000
F-Score: 6
Z-Score: 15.31
M-Score: -3.05
GuruFocus Profitability Rank ranks how profitable a company is and how likely the company’s business will stay that way. It is based on these factors:

1. Operating Margin
2. Trend of the Operating Margin (5-year average). The company with an uptrend profit margin has a higher rank.
••3. Consistency of the profitability
4. Piotroski F-Score
5. Predictability Rank•

The maximum rank is 10. A rank of 7 or higher means a higher profitability and may stay that way. A rank of 3 or lower indicates that the company has had trouble to make a profit.

Profitability Rank is not directly related to the Financial Strength Rank. But if a company is consistently profitable, its financial strength will be stronger.

Profitability & Growth : 2/10

vs
industry
vs
history
Operating margin (%) 19.20
SSRX's Operating margin (%) is ranked lower than
162% of the 657 Companies
in the Global Biotechnology industry.

( Industry Median: -69.59 vs. SSRX: 19.20 )
Ranked among companies with meaningful Operating margin (%) only.
SSRX' s 10-Year Operating margin (%) Range
Min: 8  Med: 20.70 Max: 28.6
Current: 19.2
8
28.6
Net-margin (%) 15.30
SSRX's Net-margin (%) is ranked lower than
162% of the 657 Companies
in the Global Biotechnology industry.

( Industry Median: -66.45 vs. SSRX: 15.30 )
Ranked among companies with meaningful Net-margin (%) only.
SSRX' s 10-Year Net-margin (%) Range
Min: 0.7  Med: 17.85 Max: 45.2
Current: 15.3
0.7
45.2
ROE (%) 7.50
SSRX's ROE (%) is ranked lower than
140% of the 761 Companies
in the Global Biotechnology industry.

( Industry Median: -29.50 vs. SSRX: 7.50 )
Ranked among companies with meaningful ROE (%) only.
SSRX' s 10-Year ROE (%) Range
Min: 4.3  Med: 8.60 Max: 41.6
Current: 7.5
4.3
41.6
ROA (%) 7.00
SSRX's ROA (%) is ranked lower than
126% of the 847 Companies
in the Global Biotechnology industry.

( Industry Median: -25.57 vs. SSRX: 7.00 )
Ranked among companies with meaningful ROA (%) only.
SSRX' s 10-Year ROA (%) Range
Min: 4.1  Med: 7.90 Max: 21.4
Current: 7
4.1
21.4
ROC (Joel Greenblatt) (%) 11.40
SSRX's ROC (Joel Greenblatt) (%) is ranked lower than
130% of the 817 Companies
in the Global Biotechnology industry.

( Industry Median: -333.14 vs. SSRX: 11.40 )
Ranked among companies with meaningful ROC (Joel Greenblatt) (%) only.
SSRX' s 10-Year ROC (Joel Greenblatt) (%) Range
Min: 5  Med: 10.20 Max: 35.4
Current: 11.4
5
35.4
Revenue Growth (3Y)(%) 19.00
SSRX's Revenue Growth (3Y)(%) is ranked lower than
264% of the 404 Companies
in the Global Biotechnology industry.

( Industry Median: 0.30 vs. SSRX: 19.00 )
Ranked among companies with meaningful Revenue Growth (3Y)(%) only.
SSRX' s 10-Year Revenue Growth (3Y)(%) Range
Min: 12.1  Med: 21.10 Max: 85.8
Current: 19
12.1
85.8
EBITDA Growth (3Y)(%) 12.70
SSRX's EBITDA Growth (3Y)(%) is ranked lower than
249% of the 427 Companies
in the Global Biotechnology industry.

( Industry Median: -3.90 vs. SSRX: 12.70 )
Ranked among companies with meaningful EBITDA Growth (3Y)(%) only.
SSRX' s 10-Year EBITDA Growth (3Y)(%) Range
Min: 0  Med: 12.70 Max: 114.1
Current: 12.7
0
114.1
EPS Growth (3Y)(%) 3.90
SSRX's EPS Growth (3Y)(%) is ranked lower than
258% of the 413 Companies
in the Global Biotechnology industry.

( Industry Median: -7.70 vs. SSRX: 3.90 )
Ranked among companies with meaningful EPS Growth (3Y)(%) only.
SSRX' s 10-Year EPS Growth (3Y)(%) Range
Min: -1.4  Med: 16.40 Max: 280.6
Current: 3.9
-1.4
280.6
» SSRX's 10-Y Financials

Financials


Revenue & Net Income
Cash & Debt
Oprt. Cash Flow & Free Cash Flow

» Details

Guru Trades

SSRX Guru Trades in

SSRX Guru Trades in

SSRX Guru Trades in

Q2 2013

SSRX Guru Trades in Q2 2013

Chuck Royce Sold Out
Jim Simons Sold Out
» More
» Details

Insider Trades

Latest Guru Trades with SSRX

(List those with share number changes of more than 20%, or impact to portfolio more than 0.1%)

No Entry found in the selected group of Gurus. You can
  • 1. Modify your Personalized List of Gurus, or
  • 2. Click on Premium Premium Tools above to check out all the Gurus, or
  • 3. Click on Premium Plus Premium Plus above for the stocks picks of all the institutional investment advisors (>4000)
» Interactive Charts

Peter Lynch Chart ( What is Peter Lynch Charts )

Ratios

vs
industry
vs
history
P/E(ttm) 22.50
SSRX's P/E(ttm) is ranked lower than
495% of the 215 Companies
in the Global Biotechnology industry.

( Industry Median: 41.60 vs. SSRX: 22.50 )
Ranked among companies with meaningful P/E(ttm) only.
SSRX' s 10-Year P/E(ttm) Range
Min: 11.32  Med: 20.26 Max: 35.5
Current: 22.5
11.32
35.5
PE(NRI) 22.50
SSRX's PE(NRI) is ranked lower than
500% of the 213 Companies
in the Global Biotechnology industry.

( Industry Median: 39.20 vs. SSRX: 22.50 )
Ranked among companies with meaningful PE(NRI) only.
SSRX' s 10-Year PE(NRI) Range
Min: 0  Med: 0.00 Max: 0
Current: 22.5
P/B 1.80
SSRX's P/B is ranked lower than
143% of the 747 Companies
in the Global Biotechnology industry.

( Industry Median: 4.57 vs. SSRX: 1.80 )
Ranked among companies with meaningful P/B only.
SSRX' s 10-Year P/B Range
Min: 0.71  Med: 1.44 Max: 2.66
Current: 1.8
0.71
2.66
P/S 3.44
SSRX's P/S is ranked lower than
180% of the 591 Companies
in the Global Biotechnology industry.

( Industry Median: 11.60 vs. SSRX: 3.44 )
Ranked among companies with meaningful P/S only.
SSRX' s 10-Year P/S Range
Min: 2.62  Med: 4.60 Max: 11.91
Current: 3.44
2.62
11.91
PFCF 17.70
SSRX's PFCF is ranked lower than
740% of the 144 Companies
in the Global Biotechnology industry.

( Industry Median: 45.01 vs. SSRX: 17.70 )
Ranked among companies with meaningful PFCF only.
SSRX' s 10-Year PFCF Range
Min: 11.41  Med: 21.49 Max: 100.14
Current: 17.7
11.41
100.14
EV-to-EBIT 12.20
SSRX's EV-to-EBIT is ranked lower than
475% of the 224 Companies
in the Global Biotechnology industry.

( Industry Median: 32.56 vs. SSRX: 12.20 )
Ranked among companies with meaningful EV-to-EBIT only.
SSRX' s 10-Year EV-to-EBIT Range
Min: 0.8  Med: 10.35 Max: 93.7
Current: 12.2
0.8
93.7
PEG 0.90
SSRX's PEG is ranked lower than
1459% of the 73 Companies
in the Global Biotechnology industry.

( Industry Median: 2.63 vs. SSRX: 0.90 )
Ranked among companies with meaningful PEG only.
SSRX' s 10-Year PEG Range
Min: 0.8  Med: 1.38 Max: 2.05
Current: 0.9
0.8
2.05
Shiller P/E 25.30
SSRX's Shiller P/E is ranked lower than
977% of the 109 Companies
in the Global Biotechnology industry.

( Industry Median: 49.43 vs. SSRX: 25.30 )
Ranked among companies with meaningful Shiller P/E only.
SSRX' s 10-Year Shiller P/E Range
Min: 16.93  Med: 24.97 Max: 40.8
Current: 25.3
16.93
40.8
Current Ratio 16.38
SSRX's Current Ratio is ranked lower than
131% of the 812 Companies
in the Global Biotechnology industry.

( Industry Median: 4.37 vs. SSRX: 16.38 )
Ranked among companies with meaningful Current Ratio only.
SSRX' s 10-Year Current Ratio Range
Min: 0  Med: 0.00 Max: 0
Current: 16.38
Quick Ratio 15.12
SSRX's Quick Ratio is ranked lower than
131% of the 812 Companies
in the Global Biotechnology industry.

( Industry Median: 4.23 vs. SSRX: 15.12 )
Ranked among companies with meaningful Quick Ratio only.
SSRX' s 10-Year Quick Ratio Range
Min: 0  Med: 0.00 Max: 0
Current: 15.12

Valuation & Return

vs
industry
vs
history
Price/Net Cash 2.40
SSRX's Price/Net Cash is ranked lower than
236% of the 451 Companies
in the Global Biotechnology industry.

( Industry Median: 8.40 vs. SSRX: 2.40 )
Ranked among companies with meaningful Price/Net Cash only.
SSRX' s 10-Year Price/Net Cash Range
Min: 1.4  Med: 2.30 Max: 3.6
Current: 2.4
1.4
3.6
Price/Net Current Asset Value 10.50
SSRX's Price/Net Current Asset Value is ranked lower than
198% of the 538 Companies
in the Global Biotechnology industry.

( Industry Median: 7.59 vs. SSRX: 10.50 )
Ranked among companies with meaningful Price/Net Current Asset Value only.
SSRX' s 10-Year Price/Net Current Asset Value Range
Min: 8.4  Med: 13.00 Max: 22.5
Current: 10.5
8.4
22.5
Price/Tangible Book 1.50
SSRX's Price/Tangible Book is ranked lower than
155% of the 687 Companies
in the Global Biotechnology industry.

( Industry Median: 5.90 vs. SSRX: 1.50 )
Ranked among companies with meaningful Price/Tangible Book only.
SSRX' s 10-Year Price/Tangible Book Range
Min: 1.1  Med: 1.60 Max: 2
Current: 1.5
1.1
2
Price/Projected FCF 1.20
SSRX's Price/Projected FCF is ranked lower than
678% of the 157 Companies
in the Global Biotechnology industry.

( Industry Median: 4.58 vs. SSRX: 1.20 )
Ranked among companies with meaningful Price/Projected FCF only.
SSRX' s 10-Year Price/Projected FCF Range
Min: 1.1  Med: 1.45 Max: 1.8
Current: 1.2
1.1
1.8
Price/Median PS Value 0.60
SSRX's Price/Median PS Value is ranked lower than
197% of the 540 Companies
in the Global Biotechnology industry.

( Industry Median: 1.19 vs. SSRX: 0.60 )
Ranked among companies with meaningful Price/Median PS Value only.
SSRX' s 10-Year Price/Median PS Value Range
Min: 0.7  Med: 1.00 Max: 2.4
Current: 0.6
0.7
2.4
Price/Peter Lynch Fair Value 0.80
SSRX's Price/Peter Lynch Fair Value is ranked lower than
2173% of the 49 Companies
in the Global Biotechnology industry.

( Industry Median: 2.20 vs. SSRX: 0.80 )
Ranked among companies with meaningful Price/Peter Lynch Fair Value only.
SSRX' s 10-Year Price/Peter Lynch Fair Value Range
Min: 0.8  Med: 1.40 Max: 1.4
Current: 0.8
0.8
1.4
Price/Graham Number 0.40
SSRX's Price/Graham Number is ranked lower than
623% of the 171 Companies
in the Global Biotechnology industry.

( Industry Median: 3.52 vs. SSRX: 0.40 )
Ranked among companies with meaningful Price/Graham Number only.
SSRX' s 10-Year Price/Graham Number Range
Min: 0.3  Med: 0.50 Max: 0.6
Current: 0.4
0.3
0.6
Earnings Yield (Greenblatt) (%) 8.20
SSRX's Earnings Yield (Greenblatt) (%) is ranked lower than
131% of the 813 Companies
in the Global Biotechnology industry.

( Industry Median: -5.40 vs. SSRX: 8.20 )
Ranked among companies with meaningful Earnings Yield (Greenblatt) (%) only.
SSRX' s 10-Year Earnings Yield (Greenblatt) (%) Range
Min: 1.1  Med: 9.70 Max: 120.8
Current: 8.2
1.1
120.8
Forward Rate of Return (Yacktman) (%) 21.79
SSRX's Forward Rate of Return (Yacktman) (%) is ranked lower than
1210% of the 88 Companies
in the Global Biotechnology industry.

( Industry Median: 14.22 vs. SSRX: 21.79 )
Ranked among companies with meaningful Forward Rate of Return (Yacktman) (%) only.
SSRX' s 10-Year Forward Rate of Return (Yacktman) (%) Range
Min: 2.7  Med: 18.30 Max: 22.7
Current: 21.79
2.7
22.7

Business Description

Industry: Biotechnology » Biotechnology
Compare:NVO, AMGN, GILD, BIIB, CELG » details
Traded in other countries:YFK.Germany, 83B.Germany, 01530.Hongkong,
3SBio Inc. is a fully integrated, profitable biotechnology company focused on researching, developing, manufacturing and marketing biopharmaceutical products mainly in China. 3SBio's recombinant, or genetically engineered, protein-based products and product candidates are designed to address markets with unmet medical needs in nephrology, oncology, supportive cancer care, inflammation and infectious diseases. The company's main products are EPIAO and TPIAO and its legacy products are Intefen and Inleusin. Launched in 1998, EPIAO is an injectable recombinant human erythropoietin, or EPO, that is used to stimulate the production of red blood cells in patients with anemia and to reduce the need for blood transfusions. In 2007, the company received from the SFDA licenses to produce and sell pre-filled syringe EPIAO in 2,000 IU, 3,000 IU, 4,000 IU and 10,000 IU strengths. 3SBio launched TPIAO, its newest internally developed protein-based therapeutic product, in January 2006. This product is a TPO indicated for the treatment of chemotherapy-induced thrombocytopenia, a deficiency of platelets. In addition to EPIAO and TPIAO, it markets two other protein-based therapeutic that had historically been contributors to its overall revenues. Intefen is the company's recombinant interferon alpha-2a product. Intefen is indicated for the treatment of carcinomas of the lymphatic or hematopoietic system, such as lymphoma and leukemia and viral infectious diseases, such as hepatitis C. It launched Intefen in the Chinese market in 1995. The Company's product pipeline, which it expects will be a key contributor to its future growth, consists of six product candidates in various stages of development. 3SBio's main products target markets with unmet medical needs in nephrology, oncology, supportive cancer care, inflammation and infectious disease. The company is currently focused on expanding the indication for its marketed products, developing next generation, enhanced versions of its marketed products and bringing novel protein-based therapeutics to market. 3SBio mainly sources its raw materials from a number of international suppliers through their local distributors. The company's Shenyang-based manufacturing operations consist of bulk manufacturing and formulation, fill and finish activities for the production of EPIAO, TPIAO, Intefen, Inleusin and other product candidates for both clinical and commercial purposes. 3SBio also manufactures its product candidates for clinical trials at this facility. All filling, finishing and packaging activities in relation to its domestic sales are conducted at its Shenyang facility. The company currently markets its products through distribution agreements with local agents in several developing countries, consisting of Egypt, Pakistan, Thailand, Brazil, Mexico, Trinidad and Tobago, Guatemala and Columbia. 3SBio selects its distributors based on their reputation, market coverage and sales experience. It conducts
» More Articles for SSRX

Headlines

Articles On GuruFocus.com
3SBio Inc. Announces Unaudited Second Quarter 2009 Results Aug 11 2009 

More From Other Websites
No related articles found.

Personalized Checklist

Checklist has been moved to "Checklist" tab.

Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)
FEEDBACK